These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6530875)

  • 1. Monocyte-mediated cytotoxicity on bladder cancer cells in vitro and its implication in the treatment of bladder cancer patients with bacillus Calmette-Guérin.
    Nakamura K
    Keio J Med; 1984 Nov; 33(4):185-99. PubMed ID: 6530875
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of bacillus Calmette-Guérin-induced antitumor activity in peripheral blood mononuclear cells.
    Koga S; Taniguchi K; Nishikido M; Kubota S; Yamashita S; Kanetake H; Saito Y
    Urol Int; 1991; 47 Suppl 1():80-2. PubMed ID: 1949386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monocyte cytolytic factor in promoting monocyte-mediated lysis of bladder cancer cells by bacillus Calmette-Guerin.
    Nakamura K; Chiao JW; Nagamatsu GR; Addonizio JC
    J Urol; 1987 Oct; 138(4):867-70. PubMed ID: 3116282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal monocyte function in bladder cancer patients.
    Hausman MS; Brosman SA
    J Urol; 1976 May; 115(5):537-41. PubMed ID: 1271545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six essential conditions for bladder-sparing strategies in bacillus Calmette-Guérin unresponsive bladder cancer.
    Shariat SF; Enikeev DV; Mostafaei H
    Immunotherapy; 2019 Sep; 11(13):1083-1086. PubMed ID: 31385744
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The treatment of bladder cancer with Bacillus Calmette Guerin (BCG)].
    Meretyk S; Pode D; Shapiro A
    Harefuah; 1985 Jun; 108(12):607-8. PubMed ID: 4065728
    [No Abstract]   [Full Text] [Related]  

  • 8. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR3 Down-Regulation is Involved in bacillus Calmette-Guérin Induced Bladder Tumor Growth Inhibition.
    Langle YV; Belgorosky D; Prack McCormick B; Sahores A; Góngora A; Baldi A; Lanari C; Lamb C; Eiján AM
    J Urol; 2016 Jan; 195(1):188-97. PubMed ID: 26144336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with bacillus Calmette-Guérin in patients with superficial bladder tumors. Value of monocyte activation in intravesical bacillus Calmette-Guérin therapy.
    Nissenkorn I; Lavie G; Keisari Y; Leib Z; Vilcovsky E; Servadio C; Shachter H
    Eur Urol; 1987; 13(4):246-50. PubMed ID: 2820737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance therapy with bacillus Calmette-Guerin in patients with superficial bladder cancer.
    Swibold LK
    Urol Nurs; 1999 Mar; 19(1):38-41. PubMed ID: 10373991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
    Miyazaki J; Onozawa M; Takaoka E; Yano I
    Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monocyte cytolytic factor in promoting monocyte-mediated lysis of bladder cancer cells by bacillus Calmette-Guerin.
    Catalona WJ
    J Urol; 1987 Oct; 138(4):866. PubMed ID: 3309367
    [No Abstract]   [Full Text] [Related]  

  • 14. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer.
    Alexandroff AB; Nicholson S; Patel PM; Jackson AM
    Immunotherapy; 2010 Jul; 2(4):551-60. PubMed ID: 20636008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon.
    Böhle A; Thanhäuser A; Ulmer AJ; Ernst M; Flad HD; Jocham D
    J Urol; 1993 Dec; 150(6):1932-7. PubMed ID: 8230540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.
    Lamm DL
    Nihon Hinyokika Gakkai Zasshi; 1995 Jan; 86(1):9-10. PubMed ID: 7897925
    [No Abstract]   [Full Text] [Related]  

  • 18. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
    Jakse G
    Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
    Sonoda T; Sugimura K; Ikemoto S; Kawashima H; Nakatani T
    Oncol Rep; 2007 Jun; 17(6):1469-74. PubMed ID: 17487406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer.
    Sosnowski JT
    Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.